Clearing out old cells could extend joint health, stop osteoarthritis

April 26, 2017, Johns Hopkins University School of Medicine

In a preclinical study in mice and human cells, researchers report that selectively removing old or 'senescent' cells from joints could stop and even reverse the progression of osteoarthritis.

The findings, published April 24 in Nature Medicine, support growing evidence that senescent cells contribute to age-related diseases and demonstrate that using drug therapies to remove them from the joint not only reduces the development of post-traumatic osteoarthritis, but creates an environment for new cartilage to grow and repair joints.

Senescent cells accumulate in tissues as we age and are a normal part of wound healing and injury repair. They secrete important signals that call and other cell types into damaged tissue so they can clean up and rebuild. However, in articular joints such as the knee, and in particular, these senescent cells often are not cleared from the area after injury. Their prolonged presence causes a cascade of events, which starts the development of osteoarthritis.

"Combine age-related increases in senescent cells, plus trauma, and it's a double whammy," says Jennifer Elisseeff, Ph.D., director of the translational tissue engineering center and Morton Goldberg Professor of Ophthalmology at the Johns Hopkins Wilmer Eye Institute.

The researchers took young mice and performed surgery on them, cutting their anterior cruciate ligaments (ACL) to mimic injury. The researchers then administered injections of an experimental drug named UBX0101, which was recently identified to kill senescent cells in laboratory studies.

Researchers injected UBX0101 into the mice's joints 14 days after trauma, when degradation was already starting, and observed that the presence of senescent cells was reduced by roughly 50 percent. In addition, the researchers monitored gene expression in treated mice and found that genes associated with reparative cartilage growth were activated in the joint after treatment.

Similar experiments were conducted in older mice, which showed some key differences from the treatment in younger mice. The older mice had thinner cartilage in the joint and increased pain levels before the experiment. After treatment with UBX0101 injections, the older mice exhibited reduced pain like their more youthful counterparts, but did not exhibit signs of cartilage regeneration.

To gauge the potential for UBX0101 to be translated to a human treatment, researchers tested the drug in cultures of human cartilage cells taken from donors with clinically severe osteoarthritis (i.e. patients who had undergone a total knee replacement surgery due to damage from osteoarthritis). Elisseeff's group then grew these cartilage cells into 3D structures in the lab. The 3D structures mimic how cartilage tissues grow in the body, Elisseeff explains. They then exposed these cells to UBX0101 for four days. The researchers observed that not only were the number of senescent cells dramatically reduced, but the tissue derived from these patients began forming new after the elimination of senescent cells.

"What was most striking about the results in human tissue is the fact that removal of senescent had a profound effect on tissue from very advanced osteoarthritis patients, suggesting that even patients with advanced disease could benefit," says Elisseeff.

Although the treatment appears promising, Elisseeff says one limitation in the current study is the short time that UBX101 remains in the joint. However, Unity Biotechnology, who co-developed UBX0101, is working on single-injection formulations. The researchers are hopeful that with further development, UBX0101 may one day offer a one-dose treatment for osteoarthritis. Elisseeff explains, "Because the drug targets and kills the directly, once they are eliminated, patients will not need to return for frequent treatments."

Prior to this study, Johns Hopkins Technology Ventures (JHTV), the commercialization arm of The Johns Hopkins University, licensed intellectual property around the cell technology to Unity Biotechnology Inc., a company aiming to develop therapeutics that address ; both jointly own the patent.

"The promising results from this collaboration between Johns Hopkins and Unity showcase how industry and academia can work together to develop innovative therapies," says Neil Veloso, JHTV's executive director of technology transfer. "We are excited that the results from this collaboration may develop into a product that will positively impact people around the world."

Explore further: Researchers link senescent cells to most common form of arthritis

More information: Ok Hee Jeon et al, Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment, Nature Medicine (2017). DOI: 10.1038/nm.4324

Related Stories

Researchers link senescent cells to most common form of arthritis

August 11, 2016
Researchers at Mayo Clinic have reported a causal link between senescent cells—cells that accumulate with age and contribute to frailty and disease—and osteoarthritis in mice. Their findings appear online in The Journals ...

Researchers uncover new agents

March 9, 2017
Mayo Clinic researchers have uncovered three new agents to add to the emerging repertoire of drugs that aim to delay the onset of aging by targeting senescent cells - cells that contribute to frailty and other age-related ...

Cells from cow knee joints used to grow new cartilage tissue in laboratory

January 21, 2016
In an effort to develop a method for cartilage tissue engineering, researchers at Umeå University in Sweden successfully used cartilage cells from cow knee joints. By creating a successful method with conditions conducive ...

Researchers extend lifespan by as much as 35 percent in mice

February 3, 2016
Researchers at Mayo Clinic have shown that senescent cells - cells that no longer divide and accumulate with age - negatively impact health and shorten lifespan by as much as 35 percent in normal mice. The results, which ...

Peptide targeting senescent cells restores stamina, fur, and kidney function in old mice

March 23, 2017
Regular infusions of a peptide that can selectively seek out and destroy broken-down cells that hamper proper tissue renewal, called senescent cells, showed evidence of improving healthspan in naturally-aged mice and mice ...

Research links senescent cells and atherosclerosis progression

October 27, 2016
Atherosclerosis is a disease in which arteries narrow due to plaques. That narrowing can lead to heart attacks and strokes—both of which are leading causes of death in the U.S. Now, in a paper published in Science, Mayo ...

Recommended for you

Researchers watch the knee degenerate and understand how osteoarthritis may begin

December 12, 2018
For hockey great Bobby Orr, a torn knee ligament ended his career at age 30. Orr had more than 17 knee operations, at one point having his meniscus removed—the cartilaginous tissue that helps stabilize and lubricate the ...

3-D printing offers helping hand to people with arthritis

December 11, 2018
Adaptive aids are expensive. Additive manufacturing, using low-cost 3-D printers, can save upwards of 94 percent for simple household items.

Potential arthritis treatment prevents cartilage breakdown

November 28, 2018
Osteoarthritis, a disease that causes severe joint pain, affects more than 20 million people in the United States. Some drug treatments can help alleviate the pain, but there are no treatments that can reverse or slow the ...

Patchy distribution of joint inflammation resolved

November 16, 2018
Chronic inflammatory rheumatic diseases such as rheumatoid arthritis (RA) and spondylo-arthritis (SpA) are chronic, disabling diseases with a poor outcome for loco-motoric function if left untreated. RA and SpA each affect ...

Defense against joint degeneration

October 30, 2018
During cartilage development, chondrocytes secrete the extracellular matrix (ECM) and embed within the same environment. During progressive joint disease, such as osteoarthritis (OA), dysregulation of the process can lead ...

Becoming more sensitive to pain increases the risk of knee pain not going away

October 30, 2018
Becoming more sensitive to pain, or pain sensitization, is an important risk factor for developing persistent knee pain in osteoarthritis, according to a new study by researchers at Université de Montréal and its affiliated ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.